
Vero Biotech: Innovating inhaled nitric oxide systems for unmet cardiopulmonary needs.
Founded with a mission to address the unmet medical needs of patients with cardiopulmonary conditions, Vero Biotech is an emerging biotechnology company specializing in the design, development, and commercialization of next-generation inhaled nitric oxide (NO) delivery systems. Their innovative products aim to improve the quality of life for patients by providing advanced therapeutic solutions in the biopharmaceutical market.
Vero Biotech has garnered attention for its pioneering work in inhaled nitric oxide technology, attracting notable investors and industry experts. The company's achievements include significant advancements in NO delivery systems, which have the potential to transform treatment protocols for various cardiopulmonary conditions. Through their cutting-edge research and development, Vero Biotech is making a substantial impact on the healthcare industry by offering novel solutions that enhance patient care and outcomes.

Know Bio
knowbiollc.com

Veru
verupharma.com

VirTech Bio
virtechbio.com

Verve Therapeutics
vervetx.com

Nitric Bio

Third Pole
pole3.com
Lung Biotechnology
unither.com

Respirogen
respirogen.com

Bellerophon Therapeutics be

Transpire Bio
transpirebio.com

Bi02 Medical
bio2medical.com

Verax Biomedical

BioSuperior
bio-superior.com

Verda Bio
verdabio.com

Vast Therapeutics
Companies similar to Vero Biotech include Know Bio, Veru, VirTech Bio and Verve Therapeutics.
Vero Biotech was founded in 2006.
Vero Biotech's headquarters is located in Atlanta, GA, US.
Vero Biotech's most recent funding round was for $30M (USD) in January 2023.
As of Jan 11, 2023, Vero Biotech has raised a total of $234.6M (USD).
Vero Biotech has 254 employees as of Feb 5, 2024.